Skip to main content

Closing the Gap

A roadmap to achieving
optimal care for Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is an ultra-rare but life-threatening thrombotic disorder that can lead to significant morbidity and mortality if not diagnosed and treated promptly. The condition causes small blood clots in blood vessels throughout the body, disrupting normal blood flood and supply, and leading to bleeding underneath the skin (bruising), impaired coagulation, damage to the red blood cells (which carry oxygen through the body), and organ dysfunction and failure (from lack of blood supply). There are 2 types of TTP: congenital (cTTP) and immune-mediated (acquired) (iTTP).i

The estimated annual incidence ranges from 3 to 11 cases per million peopleii.

TTP can lead to significant morbidity and mortality if not diagnosed and treated promptlyiii.

TTP is associated with a high burden of disease, including significant comorbidities such as neurological deficits, renal impairment, and cardiovascular events.iv

The first acute episode occurs in adulthood in approximately 90% of cases and less frequently during childhood.v

When untreated, acute mortality rates can reach 90% with approximately 55% to 80% of deaths occurring within 2 weeks of diagnosis.vi vii

There are several barriers to TTP optimal care, including delays in diagnosis, lack of awareness and knowledge about TTP among healthcare providers, and limited access to specialised care centres.

This site sets out some of the outcomes from the ‘Closing the gap: a roadmap to achieving optimal care for Thrombotic Thrombocytopenic Purpura’ report, which aimed at exploring these barriers in-depth and discuss potential solutions to improve the management of TTP and ultimately enhance patient outcomes.

 

Find more here:Roadmap Infographic